Search results
Results from the WOW.Com Content Network
That being said, Ozempic is a diabetes drug meant to help people with type 2 diabetes manage their blood sugar levels. So it is designed with long-term use in mind.
Diabetic retinopathy is a serious eye condition that can affect folks with diabetes. It happens when blood vessels in the eyes are damaged, potentially leading to vision loss.
This combination of blood sugar stabilization and healthy weight management can be particularly useful for those with chronic conditions like diabetes, heart disease and obesity. ... diarrhea and ...
Lung restriction in diabetes could result from chronic low-grade tissue inflammation, microangiopathy, and/or accumulation of advanced glycation end products. [46] In fact the presence restrictive lung defect in association with diabetes has been shown even in presence of obstructive lung diseases like asthma and COPD in diabetic patients. [47]
The word diarrhea is from the Ancient Greek διάρροια from διά dia "through" and ῥέω rheo "flow". Diarrhea is the spelling in American English, whereas diarrhoea is the spelling in British English. Slang terms for the condition include "the runs", "the squirts" (or "squits" in Britain [13]) and "the trots". [14] [15]
Patients with diabetes should eat preferably a balanced and healthy diet. Meals should consist of half a plate of non-starchy vegetables, 1/4 plate of lean protein, and 1/4 plate of starch/grain. [18] Patients should avoid excess simple carbs or added fat (such as butter, salad dressing) and instead eat complex carbohydrates such as whole ...
Osmotic diarrhea, distension of the small bowel leading to crampy abdominal pain, and reduced blood volume can result. Late dumping syndrome occurs 2 to 3 hours after a meal. It results from excessive movement of sugar into the intestine, which raises the body's blood glucose level and causes the pancreas to increase its release of the hormone ...
The most common adverse reactions inlude urinary tract infection, volume depletion, diarrhea, and hypoglycemia. [1] Sotagliflozin was approved for medical use in the European Union in April 2019, as Zynquista, for the treatment for type 1 diabetes, [2] and in the United States in May 2023, [3] to reduce the risk of death due to heart failure.